Cortesi, P. A., Antonazzo, I. C., Palladino, P., Gnesi, M., Mele, S., D’Amelio, M., . . . Mantovani, L. G. (2024). Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting. Acta Diabetologica, 61(8), 1017-1028. https://doi.org/10.1007/s00592-024-02276-3
Chicago-referens (17:e uppl.)Cortesi, Paolo Angelo, Ippazio Cosimo Antonazzo, Pasquale Palladino, Marco Gnesi, Silvia Mele, Marco D’Amelio, Elena Zanzottera Ferrari, Giampiero Mazzaglia, och Lorenzo Giovanni Mantovani. "Health and Economic Impact of Dapagliflozin for Type 2 Diabetes Patients Who Had or Were at Risk for Atherosclerotic Cardiovascular Disease in the Italian General Practitioners Setting." Acta Diabetologica 61, no. 8 (2024): 1017-1028. https://doi.org/10.1007/s00592-024-02276-3.
MLA-referens (9:e uppl.)Cortesi, Paolo Angelo, et al. "Health and Economic Impact of Dapagliflozin for Type 2 Diabetes Patients Who Had or Were at Risk for Atherosclerotic Cardiovascular Disease in the Italian General Practitioners Setting." Acta Diabetologica, vol. 61, no. 8, 2024, pp. 1017-1028, https://doi.org/10.1007/s00592-024-02276-3.
